论文部分内容阅读
应用酶联免疫反应(ELISA)方法,检测了广西地区368例临床各类肝病病人血清的丙型肝炎病毒抗体(抗HCV)。结果表明,各类肝病的抗HCV阳性率为38.3,％。在急肝、慢迁肝、慢活肝、重肝、肝硬化和肝癌中,抗HCV阳性率分别为15.8％(3/19)、23.1％(6/26)、21.2％(7/33)、37.5％(3/8)、44.4％(28/63)和42.9％(94/219)。抗HCV阳性率有随肝病慢性化而增高的趋势,肝硬化和肝癌的抗HCV阳性率明显高于急性或慢性肝炎患者(P<0.005),且发现HBsAg阴性肝病者的抗HCV阳性率明显高于HBsAg阳性患者。对肝癌患者的调查分析表明,HCV和HBV感染在性别、城乡、民族、文化水平等人群特征分布一致。抗HCV阳性的肝癌患者平均年龄较HBsAg阳性患者高11岁左右。
Enzyme-linked immunosorbent assay (ELISA) was used to detect hepatitis C virus antibody (anti-HCV) in 368 clinical liver disease patients in Guangxi. The results showed that all kinds of liver disease anti-HCV positive rate was 38.3%. The positive rates of anti-HCV were 15.8% (3/19), 23.1% (6/26), 21.2% (7/33) in acute liver, slow moving liver, slow living liver, severe liver, cirrhosis and liver cancer, , 37.5% (3/8), 44.4% (28/63) and 42.9% (94/219). The positive rate of anti-HCV increased with the chronicity of liver disease. The anti-HCV positive rate of cirrhosis and hepatocellular carcinoma was significantly higher than that of acute or chronic hepatitis (P <0.005), and the positive rate of anti-HCV in HBsAg negative liver disease was significantly higher In HBsAg-positive patients. Investigation and analysis of patients with liver cancer show that HCV and HBV infection are consistent in population distribution characteristics such as gender, urban and rural areas, ethnic groups, and cultural level. The average age of patients with anti-HCV-positive liver cancer is about 11 years higher than that of HBsAg-positive patients.